Bulk manufactured polyoxyalkylene polymers are commonly used in the pharmaceutical industry as excipients. Light or air can catalyze oxidative degradation of these polymers via peroxidation, which may result in functionality changes and an increase in low molecular weight fragments.
To minimize degradation, these polymers are commonly stabilized with antioxidants, some of which can have adverse biological effects [1]. To increase polymer stability, Maroon Biotech takes steps to minimize intermediates in order to produce oxidation-resistant polymers.
The MALDI spectra demonstrate the difference in quality between medical grade bulk supply P188 (Figure 1) and Maroon P188 (Figure 2). Maroon Poloxafuse® contains substantially less low molecular weight fragments.
Gel permeation chromatography (GPC, Figure 3) further demonstrates the lack of polydispersity in Maroon’s P188, and nuclear magnetic resonance (NMR, Figure 4-5) confirms the product structure compared to literature data. The 2D TOCSY spectrum’s cross-peaks (Figure 6) illustrate spin-system correlations between neighboring protons, confirming the structural integrity and relative positional sequence of the copolymer.
Poloxafuse® is Maroon Biotech’s ultra-purified, stabilized Poloxamer 188 formulation engineered specifically for scientific investigators and pharmaceutical manufacturers. Using proprietary purification techniques, we produce high-precision polyethylene glycols (PEGs), poloxamers, and tetronics with full capabilities for custom polymer synthesis.
To request product specifications or order research-grade polymers, contact our team at (312) 432-9820 or info@maroonbiotech.com.
Lanigan RS and Yamarik TA. Final report on the safety assessment of BHT(1). Int. J. Toxic. 2002; 21(2): 19-94.
